Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced on 3 ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Glucagon-like peptide-1 (GLP-1 ... and many are working on developing something similar. CagriSema: Activating amylin and GLP-1 receptors CagriSema from Novo Nordisk activates both GLP-1 and amylin ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Amylin also lowers your blood sugar levels and ... Mazdutide is both a GLP-1 agonist and a glucagon receptor agonist. It works in two ways to promote weight loss in people who are overweight ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...